Get Healthy!

People who quit taking anti-obesity meds, including popular GLP-1 receptor agonists, may regain a significant amount of weight after eight weeks, a new study finds.

Researchers discover steep increases in cancer deaths linked to obesity since 1999, especially among women, older adults and Black people.

A new study finds the combination of excess weight and heart disease in postmenopausal women is associated with an especially high risk of developing breast cancer.

A new study finds women taking GLP-1 Receptor agonists were significantly less likely to develop obesity-related cancers.

A new study finds restricting calories or eating low-fat may slightly reduce depressive symptoms, but researchers say the evidence is limited.

In a new study, researchers found no association between treatment with GLP-1 Receptor Agonists like Ozempic and Wegovy and increased risk of adverse psychiatric events.

A new study finds the more ultra-processed foods you eat, the higher your risk of dying prematurely from all causes.

A new study finds diet quality and waist-to-hip ratio strongly impact brain function as you age.

A new study finds people with pockets of fat inside their muscles are at increased risk of hospitalization of death from heart attack.

An international group of medical experts says body mass index is not a reliable way to diagnose obesity. Members of the Commission on Clinical Obesity are recommending new methods that also consider location of excess body fat and objective symptoms of disease.

A new study finds using GLP-1 receptor agonists to treat obesity in otherwise healthy adults is safe and very effective.

U.S. News & World Report, working with leading medical and nutrition experts, reveals a list of the best diets for overall health and specific conditions.

New study examines U.S. trends in body mass index and obesity and finds improving numbers, driven in part by GLP-1 weight-loss drugs.

New research shows GLP-1 agonists, like Ozempic, and SGLT2 inhibitors, like Farxiga, help lower the risk of secondary stroke, heart attack and death in stroke survivors.

A new study finds semaglutide, the active ingredient in Ozempic and Wegovy, reduced kidney damage by up to 52% in people with obesity.

Researchers are now testing a new semaglutide delivery platform that combines the medication with a special hydrogel to achieve sustained release over one month or longer.

Pregnant women with high levels of PFAS chemicals commonly found in consumer products may experience weight and heart issues later in life.

A new study finds overweight people who stay awake too late face higher odds of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke and diabetes.